vs
CPI Card Group Inc.（PMTS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CPI Card Group Inc.的1.4倍（$207.3M vs $153.1M），CPI Card Group Inc.净利率更高（4.8% vs -62.0%，领先66.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 22.3%），CPI Card Group Inc.自由现金流更多（$35.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 16.9%）
CPI Card Group Inc.是知名的支付卡生产及配套解决方案供应商，主营接触式、非接触式信用卡、借记卡、预付卡的制造与个性化定制服务，客户以北美地区的金融机构、金融科技企业及零售品牌为主。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PMTS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $153.1M | $207.3M |
| 净利润 | $7.3M | $-128.6M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 12.0% | -54.7% |
| 净利率 | 4.8% | -62.0% |
| 营收同比 | 22.3% | 25.9% |
| 净利润同比 | 8.5% | 3.5% |
| 每股收益（稀释后） | $0.62 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $153.1M | $207.3M | ||
| Q3 25 | $138.0M | $159.9M | ||
| Q2 25 | $129.8M | $166.5M | ||
| Q1 25 | $122.8M | $139.3M | ||
| Q4 24 | $125.1M | $164.6M | ||
| Q3 24 | $124.8M | $139.5M | ||
| Q2 24 | $118.8M | $147.0M | ||
| Q1 24 | $111.9M | $108.8M |
| Q4 25 | $7.3M | $-128.6M | ||
| Q3 25 | $2.3M | $-180.4M | ||
| Q2 25 | $518.0K | $-115.0M | ||
| Q1 25 | $4.8M | $-151.1M | ||
| Q4 24 | $6.8M | $-133.2M | ||
| Q3 24 | $1.3M | $-133.5M | ||
| Q2 24 | $6.0M | $-131.6M | ||
| Q1 24 | $5.5M | $-170.7M |
| Q4 25 | 31.5% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 30.9% | — | ||
| Q1 25 | 33.2% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 35.8% | — | ||
| Q2 24 | 35.7% | — | ||
| Q1 24 | 37.1% | — |
| Q4 25 | 12.0% | -54.7% | ||
| Q3 25 | 9.4% | -106.9% | ||
| Q2 25 | 7.3% | -64.8% | ||
| Q1 25 | 11.5% | -102.6% | ||
| Q4 24 | 12.7% | -74.3% | ||
| Q3 24 | 14.3% | -94.6% | ||
| Q2 24 | 12.5% | -79.1% | ||
| Q1 24 | 12.6% | -151.9% |
| Q4 25 | 4.8% | -62.0% | ||
| Q3 25 | 1.7% | -112.8% | ||
| Q2 25 | 0.4% | -69.0% | ||
| Q1 25 | 3.9% | -108.5% | ||
| Q4 24 | 5.4% | -80.9% | ||
| Q3 24 | 1.0% | -95.7% | ||
| Q2 24 | 5.1% | -89.5% | ||
| Q1 24 | 4.9% | -156.8% |
| Q4 25 | $0.62 | $-1.28 | ||
| Q3 25 | $0.19 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $0.40 | $-1.57 | ||
| Q4 24 | $0.56 | $-1.34 | ||
| Q3 24 | $0.11 | $-1.40 | ||
| Q2 24 | $0.51 | $-1.52 | ||
| Q1 24 | $0.46 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.7M | $421.0M |
| 总债务越低越好 | $286.7M | — |
| 股东权益账面价值 | $-17.3M | $-80.0M |
| 总资产 | $403.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $21.7M | $421.0M | ||
| Q3 25 | $16.0M | $202.5M | ||
| Q2 25 | $17.1M | $176.3M | ||
| Q1 25 | $31.5M | $127.1M | ||
| Q4 24 | $33.5M | $174.0M | ||
| Q3 24 | $14.7M | $150.6M | ||
| Q2 24 | $7.5M | $480.7M | ||
| Q1 24 | $17.1M | $112.3M |
| Q4 25 | $286.7M | — | ||
| Q3 25 | $308.4M | — | ||
| Q2 25 | $310.9M | — | ||
| Q1 25 | $280.7M | — | ||
| Q4 24 | $280.4M | — | ||
| Q3 24 | $280.2M | — | ||
| Q2 24 | $269.7M | — | ||
| Q1 24 | $265.3M | — |
| Q4 25 | $-17.3M | $-80.0M | ||
| Q3 25 | $-25.7M | $9.2M | ||
| Q2 25 | $-29.0M | $151.3M | ||
| Q1 25 | $-29.7M | $144.2M | ||
| Q4 24 | $-35.6M | $255.0M | ||
| Q3 24 | $-42.8M | $346.8M | ||
| Q2 24 | $-44.6M | $432.4M | ||
| Q1 24 | $-48.5M | $140.3M |
| Q4 25 | $403.2M | $1.5B | ||
| Q3 25 | $407.1M | $1.2B | ||
| Q2 25 | $399.8M | $1.3B | ||
| Q1 25 | $351.9M | $1.3B | ||
| Q4 24 | $349.7M | $1.5B | ||
| Q3 24 | $342.3M | $1.5B | ||
| Q2 24 | $321.4M | $1.6B | ||
| Q1 24 | $319.8M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $35.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 23.0% | -48.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.39× | — |
| 过去12个月自由现金流最近4个季度 | $41.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $39.6M | $-99.8M | ||
| Q3 25 | $10.0M | $-91.4M | ||
| Q2 25 | $4.3M | $-108.3M | ||
| Q1 25 | $5.6M | $-166.5M | ||
| Q4 24 | $26.7M | $-79.3M | ||
| Q3 24 | $12.5M | $-67.0M | ||
| Q2 24 | $-4.8M | $-77.0M | ||
| Q1 24 | $8.9M | $-190.7M |
| Q4 25 | $35.2M | $-100.8M | ||
| Q3 25 | $5.3M | $-92.7M | ||
| Q2 25 | $533.0K | $-110.7M | ||
| Q1 25 | $292.0K | $-167.8M | ||
| Q4 24 | $21.6M | $-79.5M | ||
| Q3 24 | $11.1M | $-68.6M | ||
| Q2 24 | $-6.0M | $-79.0M | ||
| Q1 24 | $7.4M | $-193.9M |
| Q4 25 | 23.0% | -48.6% | ||
| Q3 25 | 3.8% | -58.0% | ||
| Q2 25 | 0.4% | -66.5% | ||
| Q1 25 | 0.2% | -120.5% | ||
| Q4 24 | 17.3% | -48.3% | ||
| Q3 24 | 8.9% | -49.2% | ||
| Q2 24 | -5.0% | -53.7% | ||
| Q1 24 | 6.6% | -178.2% |
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 3.4% | 0.8% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 4.3% | 1.0% | ||
| Q4 24 | 4.0% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 1.0% | 1.4% | ||
| Q1 24 | 1.3% | 3.0% |
| Q4 25 | 5.39× | — | ||
| Q3 25 | 4.32× | — | ||
| Q2 25 | 8.39× | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | 3.94× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | -0.79× | — | ||
| Q1 24 | 1.63× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
